Resources

Open Trials- September 2020

Breast Cancer Trials:
A study of xentuzumab + everolimus and exemestane VS everolimus and exemestane in post-menopausal women with HR+ / HER2 – metastatic breast cancer and non-visceral disease (Xenera 1)
https://clinicaltrials.gov/ct2/show/NCT03659136?term=1280-0022&draw=2&rank=1

A study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate, VS Treatment of Investigator’s Choice for HER2 +, Unresectable and/or Metastatic Breast Cancer in Subjects Pretreated with Prior Standard of Care therapies including T-DM1 (DESTINY-Breast 02)
https://clinicaltrials.gov/ct2/show/NCT03523585?term=DS8201-A-U301&rank=1

A Prospective Registry study to Evaluate the Effect of the DCISionRT test on Treatment Decisions in Patient with DCIS Following Breast Conserving Therapy
https://clinicaltrials.gov/ct2/show/NCT03448926?term=preludedx&draw=2&rank=1

A Study of Tucatinib vs. Placebo in Combination with Ado-trastuzumab Emtansine (T-DM1) for patients with
Advanced of Metastatic HER2+ Breast Cancer
https://clinicaltrials.gov/ct2/show/NCT03975647?term=SGNTUC-016&draw=2&rank=1

Evaluation of IPI-549 Combined with Front-line Treatments in Pts. With Triple-Negative Breast Cancer or
Renal Cell Carcinoma
https://clinicaltrials.gov/ct2/show/NCT03961698?term=IPI-549-03&draw=2&rank=1

Biliary Tract Cancer Trials:
A Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alpha (M7824) in Participant with 1L Biliary Tract
Cancer (BTC)
https://clinicaltrials.gov/ct2/show/NCT04066491?term=MS200647&draw=2&rank=4


Lung Cancer Trials:

Assessment of Docetaxel + Plinabulin Compared to Docetaxel + Placebo in Patients With Advanced NSCLC With at Least One Measurable Lung Lesion (DUBLIN-3)
https://clinicaltrials.gov/ct2/show/NCT02504489

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
https://clinicaltrials.gov/ct2/show/NCT02973789

A Study of Pembrolizumab (Keytruda) + Lenvatinib or placebo for treatment Naïve Metastatic Non-Small Cell Lung Cancer (NSCLC) with TPS ≥ 1% (LEAP 007)
https://clinicaltrials.gov/ct2/show/NCT03829332?term=mk7902-007&draw=2&rank=1

Durvalumab vs Placebo with Stereotactic Body Radiation Therapy in Early Stage Unresected Non-Small Cell
Lung Cancer Patients (PACIFIC-4)
https://clinicaltrials.gov/ct2/show/NCT03833154?term=Pacific-4&draw=2&rank=1

Prospective Clinicogenomic Program
https://clinicaltrials.gov/ct2/show/NCT04180176?term=gx41563&draw=2&rank=1


Lymphoma Trials:

Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkin’s Lymphoma (UNITY-NHL)
https://clinicaltrials.gov/ct2/show/NCT02793583?term=unity+205&draw=2&rank=1

Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin’s Lymphoma (iNHL) (CHRONOS-4)
https://clinicaltrials.gov/ct2/show/NCT02626455?term=chronos+4&draw=2&rank=1


Prostate Cancer Trials:
A Study of Talazoparib + Enzalutamide vs Enzalutamide in Metastatic Castration-Resistant
Prostate Cancer(Talapro-2)
https://clinicaltrials.gov/ct2/show/NCT03395197?term=talapro+2&draw=2&rank=1


Urothelial Cancer Trials:
Study of Enfortumab Vedotin and Pembrolizumab, With or Without Chemotherpay, vs. Chemotherapy
Alone in Untreated Locally Advanced or MetastaticUrothelial Cancer (EV-302)
https://clinicaltrials.gov/ct2/show/NCT04223856?term=SGN22E-003&draw=2&rank=1

 

Due to our commitment to employee and patient safety regarding the COVID-19 outbreak; we continue to update and implement new company policies following recommendations of the Centers for Disease Control and Prevention (CDC) and Arizona Department of Health. Click "Learn More" for our COVID-19 Updates.Learn More